{
    "clubs": [
        {
            "name": "Al Nassr",
            "id": 1,
            "logo_img_url": "/assets/images/clubs/nasr-logo.webp",
            "name_img_url": "/assets/images/clubs/nasr-name.webp",
            "card_img_url": "/assets/images/clubs/nasr-card.webp"
        },
        {
            "name": "Al Hilal",
            "id": 2,
            "logo_img_url": "/assets/images/clubs/hilal-logo.webp",
            "name_img_url": "/assets/images/clubs/hilal-name.webp",
            "card_img_url": "/assets/images/clubs/hilal-card.webp"
        },
        {
            "name": "Real Madrid",
            "id": 3,
            "logo_img_url": "/assets/images/clubs/madrid-logo.webp",
            "name_img_url": "/assets/images/clubs/madrid-name.webp",
            "card_img_url": "/assets/images/clubs/madrid-card.webp"
        },
        {
            "name": "Barcelona",
            "id": 4,
            "logo_img_url": "/assets/images/clubs/barcelona-logo.webp",
            "name_img_url": "/assets/images/clubs/barcelona-name.webp",
            "card_img_url": "/assets/images/clubs/barcelona-card.webp"
        }
    ],
    "questions": {
        "speed_question": {
            "audio_url": "/audios/altuviiio/speed_question.mp3",
            "question": "How many birthdays does the average person have?",
            "answers": [
                {
                    "answer": "10",
                    "is_correct": false,
                    "id": 1
                },
                {
                    "answer": "18",
                    "is_correct": false,
                    "id": 2
                },
                {
                    "answer": "every year",
                    "is_correct": false,
                    "id": 3
                },
                {
                    "answer": "1",
                    "is_correct": true,
                    "id": 4
                }
            ]
        },
        "magic_questions": {
            "team1": {
                "audio_url": "/audios/altuviiio/magic-question-1.mp3",
                "question": "Under which category Altuviiio lies?",
                "answers": [
                    {
                        "answer": "SHL",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "EHL",
                        "is_correct": false,
                        "id": 2
                    },
                    {
                        "answer": "UHL",
                        "is_correct": true,
                        "id": 3
                    },
                    {
                        "answer": "NFT",
                        "is_correct": false,
                        "id": 4
                    }
                ]
            },
            "team2": {
                "audio_url": "/audios/altuviiio/magic-question-2.mp3",
                "question": "Treatment protocol of synovitis is to raise the factor activity beyond what level for at least six months?",
                "answers": [
                    {
                        "answer": "15%",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "20%",
                        "is_correct": false,
                        "id": 2
                    },
                    {
                        "answer": "30%",
                        "is_correct": true,
                        "id": 3
                    },
                    {
                        "answer": "40%",
                        "is_correct": false,
                        "id": 4
                    }
                ]
            }
        },
        "main_questions": [
            {
                "id": 1,
                "img_url": "/assets/images/players/ronaldo.webp",
                "audio_url": "/audios/altuviiio/ronaldo.mp3",
                "points": 350,
                "question": "Efanesoctocog alfa prophylaxis led to significant meaningful improvements in pain intensity outcomes:",
                "answers": [
                    {
                        "answer": "-0.12",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "-0.21",
                        "is_correct": true,
                        "id": 2
                    },
                    {
                        "answer": "-3.2",
                        "is_correct": false,
                        "id": 3
                    },
                    {
                        "answer": "-6.79",
                        "is_correct": false,
                        "id": 4
                    }
                ]
            },
            {
                "id": 2,
                "img_url": "/assets/images/players/neymar.webp",
                "audio_url": "/audios/altuviiio/neymar.mp3",
                "points": 350,
                "question": "Efanesoctocog alfa prophylaxis led to significant meaningful improvements in Haem-A-QoL (in physical health domain)",
                "answers": [
                    {
                        "answer": "-0.12",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "-0.21",
                        "is_correct": false,
                        "id": 2
                    },
                    {
                        "answer": "-3.2",
                        "is_correct": false,
                        "id": 3
                    },
                    {
                        "answer": "-6.79",
                        "is_correct": true,
                        "id": 4
                    }
                ]
            },
            {
                "id": 3,
                "img_url": "/assets/images/players/mo.webp",
                "audio_url": "/audios/altuviiio/mo.mp3",
                "points": 350,
                "question": "What was the key secondary endpoint of the intrapatient ABR reduction during the study?",
                "answers": [
                    {
                        "answer": "67%",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "77%",
                        "is_correct": true,
                        "id": 2
                    },
                    {
                        "answer": "87%",
                        "is_correct": false,
                        "id": 3
                    },
                    {
                        "answer": "97%",
                        "is_correct": false,
                        "id": 4
                    }
                ]
            },
            {
                "id": 4,
                "img_url": "/assets/images/players/messi.webp",
                "audio_url": "/audios/altuviiio/messi.mp3",
                "points": 350,
                "question": "With Efanesoctocog alfa, the Improvements in HJHS Total Score Were Observed From Baseline to Week 52 in Arm A by",
                "answers": [
                    {
                        "answer": "-0.54",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "-1.54",
                        "is_correct": true,
                        "id": 2
                    },
                    {
                        "answer": "-2.54",
                        "is_correct": false,
                        "id": 3
                    },
                    {
                        "answer": "-3.54",
                        "is_correct": false,
                        "id": 4
                    }
                ]
            },
            {
                "id": 5,
                "img_url": "/assets/images/players/salem.webp",
                "audio_url": "/audios/altuviiio/salem.mp3",
                "points": 250,
                "question": "Proportion of patient with ZERO spontaneous bleed in XTEND-1 trial",
                "answers": [
                    {
                        "answer": "50%",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "60%",
                        "is_correct": false,
                        "id": 2
                    },
                    {
                        "answer": "70%",
                        "is_correct": false,
                        "id": 3
                    },
                    {
                        "answer": "80%",
                        "is_correct": true,
                        "id": 4
                    }
                ]
            },
            {
                "id": 6,
                "img_url": "/assets/images/players/sadio.webp",
                "audio_url": "/audios/altuviiio/sadio.mp3",
                "points": 250,
                "question": "How long did Group B receive on-demand treatment with efanesoctocog alfa?",
                "answers": [
                    {
                        "answer": "24 weeks",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "26 weeks",
                        "is_correct": true,
                        "id": 2
                    },
                    {
                        "answer": "52 weeks",
                        "is_correct": false,
                        "id": 3
                    },
                    {
                        "answer": "54 weeks",
                        "is_correct": false,
                        "id": 4
                    }
                ]
            },
            {
                "id": 7,
                "img_url": "/assets/images/players/vinicius.webp",
                "audio_url": "/audios/altuviiio/vinicius.mp3",
                "points": 250,
                "question": "What percentage of bleeding episodes in the overall population resolved with one injection of efanesoctocog alfa?",
                "answers": [
                    {
                        "answer": "65%",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "80%",
                        "is_correct": false,
                        "id": 2
                    },
                    {
                        "answer": "97%",
                        "is_correct": true,
                        "id": 3
                    },
                    {
                        "answer": "100%",
                        "is_correct": false,
                        "id": 4
                    }
                ]
            },
            {
                "id": 8,
                "img_url": "/assets/images/players/pedri.webp",
                "audio_url": "/audios/altuviiio/pedri.mp3",
                "points": 250,
                "question": "In the XTEND‑ed long‑term extension, how were target joints defined and what outcome was observed after ≥12 months of efanesoctocog alfa prophylaxis?",
                "answers": [
                    {
                        "answer": "Defined as ≥1 bleed/year; most target joints persisted despite prophylaxis",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "Defined as ≥2 bleeds/year; ~50% of target joints resolved",
                        "is_correct": false,
                        "id": 2
                    },
                    {
                        "answer": "Defined as ≥3 spontaneous bleeds in 6 months; all evaluable target joints resolved after ≥12 months of prophylaxis",
                        "is_correct": true,
                        "id": 3
                    },
                    {
                        "answer": "Defined as ≥3 traumatic bleeds in 12 months; resolution was not assessed",
                        "is_correct": false,
                        "id": 4
                    }
                ]
            },
            {
                "id": 9,
                "img_url": "/assets/images/players/malcom.webp",
                "audio_url": "/audios/altuviiio/malcom.mp3",
                "points": 100,
                "question": "For monitoring FVIII activity with efanesoctocog alfa using a one‑stage clotting assay, which aPTT reagent is specifically referenced as the one used throughout clinical development?",
                "answers": [
                    {
                        "answer": "Actin FS",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "Actin FSL",
                        "is_correct": true,
                        "id": 2
                    },
                    {
                        "answer": "SynthASil",
                        "is_correct": false,
                        "id": 3
                    },
                    {
                        "answer": "TriniCLOT APTT HS",
                        "is_correct": false,
                        "id": 4
                    }
                ]
            },
            {
                "id": 10,
                "img_url": "/assets/images/players/otavio.webp",
                "audio_url": "/audios/altuviiio/otavio.mp3",
                "points": 100,
                "question": "XTEND‑1: mean ABR on weekly efanesoctocog prophylaxis was closest to:",
                "answers": [
                    {
                        "answer": "0.5",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "0.6",
                        "is_correct": false,
                        "id": 2
                    },
                    {
                        "answer": "0.7",
                        "is_correct": true,
                        "id": 3
                    },
                    {
                        "answer": "1.7",
                        "is_correct": false,
                        "id": 4
                    }
                ]
            },
            {
                "id": 11,
                "img_url": "/assets/images/players/luka.webp",
                "audio_url": "/audios/altuviiio/luka.mp3",
                "points": 100,
                "question": "Which limitation of gene therapy for hemophilia A is commonly highlighted in different researches?",
                "answers": [
                    {
                        "answer": "It provides fully predictable, stable FVIII levels across all patients",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "It eliminates the need for long‑term follow‑up after infusion",
                        "is_correct": false,
                        "id": 2
                    },
                    {
                        "answer": "Durability/variability of FVIII expression remains uncertain and requires long‑term monitoring",
                        "is_correct": true,
                        "id": 3
                    },
                    {
                        "answer": "It is routinely used in patients with active inhibitors and significant liver disease",
                        "is_correct": false,
                        "id": 4
                    }
                ]
            },
            {
                "id": 12,
                "img_url": "/assets/images/players/gavi.webp",
                "audio_url": "/audios/altuviiio/gavi.mp3",
                "points": 100,
                "question": "Hemlibra SmPC: loading regimen is:",
                "answers": [
                    {
                        "answer": "1.5 mg/kg weekly ×4",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "3 mg/kg weekly ×4",
                        "is_correct": true,
                        "id": 2
                    },
                    {
                        "answer": "6 mg/kg every 4 weeks ×4",
                        "is_correct": false,
                        "id": 3
                    },
                    {
                        "answer": "50 IU/kg weekly ×4",
                        "is_correct": false,
                        "id": 4
                    }
                ]
            },
            {
                "id": 13,
                "img_url": "/assets/images/players/ali.webp",
                "audio_url": "/audios/altuviiio/ali.mp3",
                "points": 50,
                "question": "ALTUVOCT/ALTUVIIIO label guidance: for minor/moderate bleeds occurring within 2–3 days after a prophylaxis dose",
                "answers": [
                    {
                        "answer": "Switch to another treatment",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "30 IU/kg dose option may be used",
                        "is_correct": true,
                        "id": 2
                    },
                    {
                        "answer": "100 IU/kg dose option may be used",
                        "is_correct": false,
                        "id": 3
                    },
                    {
                        "answer": "Use only for life‑threatening bleeds",
                        "is_correct": false,
                        "id": 4
                    }
                ]
            },
            {
                "id": 14,
                "img_url": "/assets/images/players/abdulrahman.webp",
                "audio_url": "/audios/altuviiio/abdulrahman.mp3",
                "points": 50,
                "question": "In a patient on Emicizumab, FVIII activity (endogenous or infused FVIII) should be measured using:",
                "answers": [
                    {
                        "answer": "aPTT‑based one‑stage FVIII assay",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "Human‑reagent chromogenic FVIII assay",
                        "is_correct": false,
                        "id": 2
                    },
                    {
                        "answer": "PT‑based single‑factor assay",
                        "is_correct": false,
                        "id": 3
                    },
                    {
                        "answer": "Bovine‑reagent chromogenic FVIII assay",
                        "is_correct": true,
                        "id": 4
                    }
                ]
            },
            {
                "id": 15,
                "img_url": "/assets/images/players/lucas.webp",
                "audio_url": "/audios/altuviiio/lucas.mp3",
                "points": 50,
                "question": "ALTUVOCT/ALTUVIIIO label guidance: after major surgery, additional doses may be given:",
                "answers": [
                    {
                        "answer": "Every 8 hours",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "Daily",
                        "is_correct": false,
                        "id": 2
                    },
                    {
                        "answer": "Every 2-3 days",
                        "is_correct": true,
                        "id": 3
                    },
                    {
                        "answer": "Weekly",
                        "is_correct": false,
                        "id": 4
                    }
                ]
            },
            {
                "id": 16,
                "img_url": "/assets/images/players/sergi.webp",
                "audio_url": "/audios/altuviiio/sergi.mp3",
                "points": 50,
                "question": "Why are subclinical bleeds clinically important?",
                "answers": [
                    {
                        "answer": "They prolong PT",
                        "is_correct": false,
                        "id": 1
                    },
                    {
                        "answer": "They contribute to joint damage",
                        "is_correct": true,
                        "id": 2
                    },
                    {
                        "answer": "They prevent inhibitor formation",
                        "is_correct": false,
                        "id": 3
                    },
                    {
                        "answer": "They raise platelet count",
                        "is_correct": false,
                        "id": 4
                    }
                ]
            }
        ]
    }
}